Skip to main content

Advertisement

SpringerLink
Log in

Heart failure with normal ejection fraction

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Heart failure with normal ejection fraction, also known as diastolic heart failure, is a major problem for patients and health-care providers and is a substantial expense to society. The main pathophysiologic processes involved are increased left ventricular stiffness and abnormal relaxation, with resulting impaired left ventricular filling. These processes typically displace the pressure-volume relationship in an upward direction, resulting in increased left ventricular end-diastolic, left atrial, and pulmonary capillary wedge pressures, leading to symptoms of pulmonary congestion. The most common clinical disorders leading to diastolic heart failure are 1) hypertension with concentric left ventricular hypertrophy, 2) coronary artery disease with decreased left ventricular compliance, 3) hypertrophic cardiomyopathy, and 4) aortic stenosis with concentric left ventricular hypertrophy. Echocardiography and cardiac catheterization with magnetic resonance imaging hold promise as future diagnostic tools. The approach to the treatment of diastolic heart failure is focused on four treatment goals: 1) persistent control of elevated blood pressure, with regression of left ventricular hypertrophy, 2) careful reduction of central blood volume (diuretics), 3) maintenance of atrial contraction and control of heart rate (beta-blockers, digoxin, atrioventricular pacing); and 4) improvement of left ventricular relaxation. There is currently no drug treatment specific for abnormal relaxation, although efforts are being made to develop such compounds. A promising future therapy includes agents that lyse advanced glycation end-products as an approach to relieving increased ventricular stiffness. In addition to pharmacotherapy, maintaining ideal body weight and a regular exercise program are also helpful in the treatment of diastolic heart failure. Although the overall prognosis of patients with diastolic dysfunction is more favorable than that of patients with systolic dysfunction, the frequency of treatment failure and recurrent symptoms underscores the need for further improvement in treatment of this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Int Med 1992, 117:502–510.

    PubMed  CAS  Google Scholar 

  2. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995, 26:1565–1574.

    Article  PubMed  CAS  Google Scholar 

  3. Vasan RS, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948–1955. This article details the prevalence and prognosis of patients with DHF.

    Article  PubMed  CAS  Google Scholar 

  4. Mosterd A, Hoes AW, de Bruyne MC, et al.: Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam study. Eur Heart J 1999, 20:447–455.

    Article  PubMed  CAS  Google Scholar 

  5. Kupari M, Lindroos M, Iivanainen AM, et al.: Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Aging Study. J Intern Med 1997, 241:387–394.

    Article  PubMed  CAS  Google Scholar 

  6. Senni M, Tribouilloy CM, Rodeheffer RJ, et al.: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998, 98:2282–2289.

    PubMed  CAS  Google Scholar 

  7. Brogan WC 3rd, Hillis LD, Flores ED, et al.: The natural history of isolated left ventricular diastolic dysfunction. Am J Med 1992, 92:627–630.

    Article  PubMed  Google Scholar 

  8. Cohn JN, Johnson G: Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990 81:III48–53.

    PubMed  CAS  Google Scholar 

  9. McDermott MM, Feinglass J, Lee PI, et al.: Systolic function, readmission rates and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997, 134:728–736.

    Article  PubMed  CAS  Google Scholar 

  10. O’Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994, 13:S107-S112.

    PubMed  CAS  Google Scholar 

  11. Dauterman KW, Massie BM, Gheorghiade M: Heart failure associated with preserved systolic function: a common and costly clinical entity. Am Heart J 1998, 135:S310-S319.

    Article  PubMed  CAS  Google Scholar 

  12. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997, 18:736–753.

    Google Scholar 

  13. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83:1A-38A.

  14. Vasan RS, Levy D: Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000, 101:2118–2121. This article is the first to attempt to develop uniform criteria for the diagnosis of DHF.

    PubMed  CAS  Google Scholar 

  15. Mandinov L, Eberli FR, Seiler C, et al.: Diastolic heart failure. Cardiovasc Res 2000, 45:813–825. An excellent review article.

    Article  PubMed  CAS  Google Scholar 

  16. Kiode M, Carabello BA, Conrad CC, et al.: Hypertrophic response to hemodynamic overload: role of load vs. rennin-angiotensin system activation. Am J Physiol 1999, 276:H350-H358.

    Google Scholar 

  17. Sadoshima J, Xu Y, Slayter HS, et al.: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977–984.

    Article  PubMed  CAS  Google Scholar 

  18. Susic D, Nunez E, Frohlich ED, et al.: Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension 1996, 28:265–268.

    PubMed  CAS  Google Scholar 

  19. Lamb HJ, Beyerbacht HP, vander Laarse A, et al.: Diastolic dysfunction in hypertensive heart disease associated with altered myocardial metabolism. Circulation 1999, 99:2261–2267.

    PubMed  CAS  Google Scholar 

  20. Heyndrickx GR, Paulus WJ: Effect of asynchrony on left ventricular relaxation. Circulation 1990, 81:III41–47.

    PubMed  CAS  Google Scholar 

  21. Arai M, Matsui H, Periasamy M: Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 1994, 74:555–564.

    PubMed  CAS  Google Scholar 

  22. Paulus WJ, Heyndrickx GR, Nellens P, et al.: Impaired relaxation of the hypertrophied left ventricle in aortic stenosis: effects of aortic valvuloplasty and postextrasystolic potentiation. Eur Heart J 1988, 9(suppl E):25–30.

    PubMed  Google Scholar 

  23. Villari B, Hess OM, Kaufmann P, et al.: Effect of aortic valve stenosis (pressure overload) and regurgitation (volume overload) on left ventricular systolic and diastolic function. Am J Cardiol 1992, 69:927–934.

    Article  PubMed  CAS  Google Scholar 

  24. Villari B, Campbell SE, Hess OM, et al.: Influence of collagen network on left ventricular systolic and diastolic function in aortic valvular disease. J Am Coll Cardiol 1993, 22:1477–1484.

    Article  PubMed  CAS  Google Scholar 

  25. Villari B, Vassali G, Monrad ES, et al.: Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995, 91:2353–2358.

    PubMed  CAS  Google Scholar 

  26. Monrad ES, Hess OM, Marukami T, et al.: Abnormal exercise hemodynamics in patients with normal systolic function late after aortic valve replacement. Circulation 1988, 77:613–624.

    PubMed  CAS  Google Scholar 

  27. Hausdorf G, Siglow V, Neinaber CA: Effects of increasing afterload on early diastolic dysfunction in hypertrophic non-obstructive cardiomyopathy. Br Heart J 1988, 60:240–246.

    PubMed  CAS  Google Scholar 

  28. Gwathmey JK, Warren SE, Briggs GM, et al.: Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on force generation during systole. J Clin Invest 1991, 87:1023–1031.

    Article  PubMed  CAS  Google Scholar 

  29. Zeiman SJ, Fortuin NJ: Hypertrophic and restrictive cardiomyopathies in the elderly. Cardiol Clin 1999, 17:159–172.

    Article  Google Scholar 

  30. Dumesnil JG, Gaudreault G, Honos GN, et al.: Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension. Am J Cardiol 1991, 68:515–519.

    Article  PubMed  CAS  Google Scholar 

  31. Gottdeiner JS: Clinical trials of single-drug therapy for the cardiac effects of hypertension. Am J Hypertens 1999, 12:12s-18s.

    Article  Google Scholar 

  32. Betocchi S, Chiariello M: Effects of calcium antagonists on left ventricular structure and function. J Hypertens Suppl 1993, 11:S33-S37.

    Article  PubMed  CAS  Google Scholar 

  33. Iliceto S: Left ventricular dysfunction: which role for calcium antagonists? Eur Heart J 1997, 18(suppl A):87–91.

    Google Scholar 

  34. Mitsunami K, Inoue S, Maeda K, et al.: Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998, 12:469–474.

    Article  PubMed  CAS  Google Scholar 

  35. Angomachalelis N, Hourzamanis AI, Sideri S, et al.: Improvement of left ventricular diastolic dysfunction in hypertensive patients 1 month after ACE inhibition therapy: evaluation by ultrasonic automated boundary detection. Heart Vessels 1996, 11:303–309.

    Article  PubMed  CAS  Google Scholar 

  36. Silvestre JS, Heymes C, Oubenaissa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction: effect of an angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694–2701.

    PubMed  CAS  Google Scholar 

  37. Degre S, Detry JM, Unger P, et al.: Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol 1998, 53:261–267.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Texas Heath Science Center at San Antonio, 7703 Floyd Curl Drive, 78229, San Antonio, TX, USA

    Mauro Ortiz MD & Gregory L. Freeman MD

Authors
  1. Mauro Ortiz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory L. Freeman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ortiz, M., Freeman, G.L. Heart failure with normal ejection fraction. Curr Treat Options Cardio Med 3, 507–513 (2001). https://doi.org/10.1007/s11936-001-0024-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-001-0024-7

Keywords

Search

Navigation